Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Kuur Therapeutics, a US-based cancer T-cell therapy developer, officially launched yesterday with an undisclosed sum to catalyse research from academic health science centre Baylor College of Medicine’s Center for Cell and Gene Therapy. The funding was supplied by Baylor College of Medicine, commercialisation firm IP Group and asset management firm Schroder Adveq. Kuur Therapeutics’ immunotherapy platform is expected to treat cancer using an engineered white blood cell that possesses characteristics of both T and NK-type cells. The company is a reboot of defunct cellular immunotherapy developer Cell Medica, whose most recent round, a series C, closed at $73m in 2017 with commercialisation firm Touchstone Innovations (since acquired by IP Group), Invesco Perpetual and Woodford Investment Management.
